Velaglucerase Alfa: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Velaglucerase Alfa. Educational only — not medical advice.
Labeled uses
VPRIV is indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
Source: FDA labeling via NIH DailyMed (set ca02f7a4…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.